Form 4: YK Bioventures Sells 3.25 Million Shares of Cero Therapeutics at Average Price of $0.10

YK Bioventures Opportunities Fund I, L.P. sold 3,250,000 shares of Cero Therapeutics Holdings, Inc. at an average price of $0.10 per share.

Summary

• YK Bioventures Opportunities Fund I, L.P. sold 3,250,000 shares of Cero Therapeutics Holdings, Inc. common stock.
• The sales occurred on October 10, 2024.
• The shares were sold at prices ranging from $0.09 to $0.10 per share, with a weighted average price of $0.10.
• Following the transaction, YK Bioventures Opportunities Fund I, L.P. still beneficially owns 22,620,783 shares of Cero Therapeutics.
• The shares are indirectly held through YK Bioventures Opportunities Fund I, L.P.
• YK Bioventures Opportunities GP I, LLC is the general partner of YK Bioventures Opportunities Fund I, L.P. and may be deemed to beneficially own the shares.
• Mitchell W. Kossar and Gary K. Yeung, managing partners of YK Opps I GP, may be deemed to share voting and investment power over the shares.

Sentiment

Score: 3

Explanation: The sale of a large block of shares by a major shareholder is generally a negative signal, suggesting a lack of confidence or a need to rebalance the portfolio. This could lead to downward pressure on the stock price.

Negatives

• The sale of 3,250,000 shares by a major shareholder could be perceived negatively by the market.

Risks

• Continued selling pressure from YK Bioventures could further depress the stock price.
• The sale may indicate a lack of confidence in the company's future prospects by a major shareholder.

Management Comments

• YK Bioventures Opportunities GP I, LLC, Mitchell W. Kossar, and Gary K. Yeung disclaim beneficial ownership of these shares except to the extent of their respective pecuniary interest therein.

Industry Context

This transaction is a common occurrence in the biotech industry where investment firms often adjust their holdings based on various factors, including portfolio management and market conditions. The sale by YK Bioventures could be a routine portfolio adjustment or a strategic move based on their assessment of Cero Therapeutics.

Comparison to Industry Standards

• Sales of this size by major shareholders are not uncommon in the biotech sector, especially for companies with volatile stock prices.
• Similar transactions can be seen with other biotech firms where venture capital or private equity firms adjust their positions after a period of investment.
• For example, similar sales have been observed in companies like Xencor and Iovance Biotherapeutics, where large shareholders periodically reduce their holdings.

Stakeholder Impact

• The sale could negatively impact shareholder confidence and potentially lead to a decrease in the stock price.
• Employees may be concerned about the implications of a major shareholder reducing their stake.

Key Dates

Keywords

Cero Therapeutics, YK Bioventures, share sale, stock transaction, beneficial ownership, Form 4, SEC filing